产品
编 号：F743596
产品类型
规格
价格
是否有货
结构图
CAS No: 1257358-38-5
产品详情
生物活性：
Gontivimab (ALX-0171; VR-465) is a poent anti-RSV prefusion F protein nanobody with a KD value of 0.113 nM. Gontivimab shows antiviral activity. Gontivimab reduces the RSV load in the nose and lung.
体内研究：
Gontivimab (1-68 mg/kg；鼻内给药或雾化) 降低大鼠鼻腔和肺部的 RSV 负荷。Animal Model:Rats (RSV Tracy)
Dosage:1-68 mg/kg
Administration:Intranasal administration or nebulization; once (day 2 or day 3) or twice (day 2 and day 3)
Result:Resulted in significant viral load reductions in the lungs ranging.
体外研究：
Gontivimab (0-100000 nM) 显示出抗病毒活性，对 RSV-A、RSV-B 18537 菌株的 IC50 分别为 0.1、0.4 nM。Gontivimab 与 F 蛋白的抗原位点 II 结合。
Gontivimab (ALX-0171; VR-465) is a poent anti-RSV prefusion F protein nanobody with a KD value of 0.113 nM. Gontivimab shows antiviral activity. Gontivimab reduces the RSV load in the nose and lung.
体内研究：
Gontivimab (1-68 mg/kg；鼻内给药或雾化) 降低大鼠鼻腔和肺部的 RSV 负荷。Animal Model:Rats (RSV Tracy)
Dosage:1-68 mg/kg
Administration:Intranasal administration or nebulization; once (day 2 or day 3) or twice (day 2 and day 3)
Result:Resulted in significant viral load reductions in the lungs ranging.
体外研究：
Gontivimab (0-100000 nM) 显示出抗病毒活性，对 RSV-A、RSV-B 18537 菌株的 IC50 分别为 0.1、0.4 nM。Gontivimab 与 F 蛋白的抗原位点 II 结合。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备